Navigation Links
One Step Closer: Novel Opioid Receptor Compound in Phase I Clinical Trials
Date:5/8/2009

iglass from McGill University, a Kentucky bluegrass hybrid from Rutgers, and even television's V-Chip from Simon Fraser University), among others.

Founded in the 1990s, Rensselaer's Office of Technology Commercialization (OTC), affiliated with the Incubator Program and the Rensselaer Technology Park, helps the Institute protect intellectual property and forges relationships with industry to bring Rensselaer's discoveries to the marketplace. The OTC also contributes to the local economy by spinning off new companies that are based upon technology developed by university faculty, students, and researchers. Discoveries in nanotechnology, electronics, energy, biotechnology, and terahertz are all part of the Institute's expanding intellectual property portfolio and reflect Rensselaer's aggressive, expanding research initiative.

The initial research leading to Wentland's latest discovery was funded in 1999 through a $826,000 grant from the National Institutes of Health/National Institute on Drug Abuse (NIH-NIDA) in an effort to discover novel drugs to treat cocaine abuse. In 2002, Wentland's NIH grant was renewed for an additional $1.6 million, and he was awarded new funding from Albany Molecular Research Inc. for a postdoctoral associate position. In 2007, the NIH grant was renewed again for $1.25 million.

"My life's ambition has been to identify a compound that's actually helping people. That has been my entire focus for the last 39 years," Wentland said. He had a choice: Go the traditional route of publishing findings in a scientific journal and then seek additional research grants, or try for development and clinical trials through a licensing agreement with a pharmaceutical company. Given that therapeutics are largely developed by such companies, Wentland said the decision wasn't difficult. He began discussions with the OTC.

After six years of work, which included the
'/>"/>

SOURCE Rensselaer Polytechnic Institute
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Novel Technology Breaks Through Cancer Pain
2. Iomai Trial Shows 100 Percent Immune Response in Elderly Subjects Vaccinated With Novel Travelers Diarrhea Patch Vaccine
3. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
4. Quark Pharmaceuticals Files Patent Application Covering Novel Chemical Modifications to its RNAi Molecules
5. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
6. The Lancet Publishes Major Phase 3 Study on Novel Oral Direct Thrombin Inhibitor
7. Study Results for Aclidinium Bromide, a Novel Anticholinergic, Presented at European Respiratory Society Annual Congress
8. Phase 2 Clinical Studies Initiated for a Novel Therapeutic Candidate Identified Through Pharmacopeia Collaboration
9. Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development
10. ECLIPSE Data on Effects of Otsukas Investigational Novel Treatment, Tolvaptan, on Advanced Heart Failure Patients Hemodynamics and Urine Output Featured in Heart Failure Society of Americas Late Breaking Trials
11. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2015)... 2015 PharmaPoint: Type 1 Diabetes - Global Drug ... 1 diabetes (T1D) is an autoimmune disease that permanently destroys ... body can no longer produce insulin. Over the last 90 ... no other treatment can be offered to a patient who ... with different times of action - long-acting as well as ...
(Date:5/27/2015)... , May 27, 2015 The prevalence of ... by accelerated aging of population and changes in consumption ... has been growing year after year, thereby promoting the ... cases in China totaled 454,505 ... the interventional cardiovascular device industry there was worth RMB20.12 ...
(Date:5/27/2015)... 27, 2015 Research ... addition of the  "Asia Pacific Ultrasound Devices ... - 2019)"  company profile to their ... , ,Ultrasound is a type of imaging. ... at body parts and structures inside the ...
Breaking Medicine Technology:PharmaPoint: Type 1 Diabetes - Global Drug Forecast and Market Analysis to 2023 2PharmaPoint: Type 1 Diabetes - Global Drug Forecast and Market Analysis to 2023 3PharmaPoint: Type 1 Diabetes - Global Drug Forecast and Market Analysis to 2023 4China Interventional Cardiovascular Device Industry Report, 2014-2017 2China Interventional Cardiovascular Device Industry Report, 2014-2017 3Asia Pacific Ultrasound Devices Market Report 2015 - Growth, Trends And Forecasts 2014 - 2019 2
... Astellas Pharma US, Inc. ("Astellas") recently hired Mark ... oncology. Reporting directly to Patrick Shea, senior vice ... responsible for all U.S. commercial activities supporting marketed ... lead commercial planning for early stage development compounds. ...
... The Targetech Innovation Center, supported by a strategic ... developing pipeline of biomedical device opportunities poised to begin ... "This is an exciting development in the strategic ... effort, we will see more companies locating to Akron. ...
Cached Medicine Technology:Astellas Announces Vice President of Sales and Marketing for U.S. Oncology Franchise 2Akron Relationship with Israeli Incubator, Targetech, Shows Promise 2Akron Relationship with Israeli Incubator, Targetech, Shows Promise 3
(Date:5/27/2015)... (PRWEB) May 27, 2015 “ Nursing Homes ... care ,” reads the title of a recent April 2015 ... take elderly loved ones to the hospital, 20-plus years of ... This research shows that high-quality nursing homes are both safer ... With the quality of nursing homes varying widely, patients and ...
(Date:5/27/2015)... While hair transplantation has been used successfully ... study conducted by a physician member of the International ... follicle grafting can help treat patients with non-healing chronic ... ISHRS, which offers research grants for the purpose of ... In the past decade, numerous scientific studies have corroborated ...
(Date:5/27/2015)... The new http://www.carsonenergy.com includes ... should consider oil and gas investing, the substantial tax ... drilled, industry news, IRA investing, definitions and acronyms, info-graphics ... knowledge and experience is now in one central location, ... able to access 24 hours a day, 7 days ...
(Date:5/27/2015)... (PRWEB) May 27, 2015 CURE® ... (BCAN) , whose mission is to advance research, provide ... have joined forces to battle the fifth most common ... the bladder’s lining start to grow out of control. ... their families at every stage of the cancer experience ...
(Date:5/27/2015)... Difass USA, a modern supplement brand committed ... first three flagship products, Dormiva™, Relaxiva™ and Reminiva™. All ... http://www.difassusa.com . , A restful night’s sleep is ... people struggle with getting the full amount of sleep ... designed to help you fall asleep and stay asleep, ...
Breaking Medicine News(10 mins):Health News:BestNursingHomes.com Launches on National Senior Health and Fitness Day 2Health News:New Research Finds Hair Grafting a Promising Therapy for Chronic Leg Ulcers - International Society of Hair Restoration Surgery Awards Research Grant 2Health News:New Research Finds Hair Grafting a Promising Therapy for Chronic Leg Ulcers - International Society of Hair Restoration Surgery Awards Research Grant 3Health News:Carson Energy Launches Next Generation Investor Website 2Health News:CURE® Magazine and Bladder Cancer Advocacy Network Align to Increase Awareness of Fifth Most Common Type of Cancer 2Health News:CURE® Magazine and Bladder Cancer Advocacy Network Align to Increase Awareness of Fifth Most Common Type of Cancer 3Health News:Supplement Brand Difass USA Launches in the U.S. with Three Flagship Products Designed to Bring Balance Back to Your Life 2
... HealthDay Reporter , FRIDAY, April 27 (HealthDay News) -- Although ... to carry inhalers at school and 48 states have laws ... say that some kids are still being denied access ... school district handles this a little bit different, and for ...
... , FRIDAY, April 27 (HealthDay News) -- Given the ... shows that children prefer a living creature. Even babies ... animals, including those that may frighten many adults, such as ... Rutgers University found. The researchers conducted three separate experiments ...
... who are bullied are three times more likely than others to ... a new study. A team of researchers from the ... April 27 in the BMJ , could help identify those ... of self-harming behaviors included cutting and biting arms, pulling out clumps ...
... 26, 2012 - The mitotic spindle, an apparatus that ... than the standard textbook picture suggests, according to researchers ... (SEAS). The findings, which result from quantitative measurements ... journal Cell . The researchers used a ...
... Rochester Medical Center are testing whether different doses of an ... a standard dose in people with mild hypertension, possibly with ... launched clinical trial, funded with a $1.9 million grant from ... of its kind in the United States. The ...
... HealthDay Reporter , THURSDAY, April 26 (HealthDay News) -- ... help keep your brain functioning well as you age, new ... the highest intake of berries appeared to delay cognitive aging ... such as thinking, remembering and reasoning. "Given that ...
Cached Medicine News:Health News:Some Schools Don't Let Kids Carry Asthma Inhalers 2Health News:Some Schools Don't Let Kids Carry Asthma Inhalers 3Health News:Bullied Children at Greater Risk for Self-Harm, Study Finds 2Health News:Slicing mitotic spindle with lasers, nanosurgeons unravel old pole-to-pole theory 2Health News:URMC clinical trial tests new regimen for hypertension 2Health News:Eating Berries Might Help Preserve Your Memory 2Health News:Eating Berries Might Help Preserve Your Memory 3
... macular health. Snellen charts available ... Easy to mount on most ... in a few minutes. Rapid ... Retinal vision testing without refraction ...
Eye Q Lite is ideal for color and red-free imaging used in general clinical and optometric casework such as anterior segmenting and diabetic screening....
The Genesis Camera meets the needs of those with specific requirements that cannot be met by a conventional 'chinrest' type camera....
The quick access to diabetic screening, panoramic images of the retina including peripheral area are available by using easy, semi automatic guidance of peripheral fixation....
Medicine Products: